NZX-listed AFT Pharmaceuticals has declared a maiden dividend after record revenue to the end of March 2023, as it looks to start selling its flagship pain relief product Maxigesic into the US market early next year.
The Auckland-based pharmaceutical company’s share price surged 9% in early
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
